T. Rowe Price Health Sciences Fund, Inc. is a registered fund series of T. ROWE PRICE HEALTH SCIENCES FUND, INC. (series S000002088). Net assets $10.9B as of 2026-03-31.
Showing 15 of 200 holdings by value.
| Holding | Ticker | Value | % of fund |
|---|---|---|---|
| ELI LILLY & CO | — | $1.1B | 1013.62% |
| THERMO FISHER SCIENTIFIC INC | — | $442.9M | 406.54% |
| INTUITIVE SURGICAL INC | — | $397.9M | 365.30% |
| STRYKER CORP | — | $377.1M | 346.14% |
| MERCK & CO. INC. | — | $374.9M | 344.13% |
| ASTRAZENECA PLC | — | $345.4M | 317.06% |
| UNITEDHEALTH GROUP INC | — | $336.3M | 308.73% |
| ARGENX SE - ADR | — | $317.9M | 291.82% |
| ABBVIE INC | — | $309.6M | 284.18% |
| REGENERON PHARMACEUTICALS | — | $288.4M | 264.72% |
| GILEAD SCIENCES INC | — | $283.6M | 260.34% |
| JOHNSON & JOHNSON | — | $266.0M | 244.22% |
| VERTEX PHARMACEUTICALS INC | — | $264.0M | 242.38% |
| DANAHER CORP | — | $222.9M | 204.59% |
| ALNYLAM PHARMACEUTICALS INC | — | $176.0M | 161.56% |
| Report date | Net assets |
|---|---|
| 2026-03-31 | $10.9B |
| 2025-12-31 | $12.1B |
| 2025-09-30 | $11.0B |
| 2025-06-30 | $11.3B |
| 2025-03-31 | $12.3B |
| 2024-12-31 | $13.0B |
| 2024-09-30 | $15.4B |
| 2024-06-30 | $14.9B |